The efficient export of a subset ofEscherichia coli envelope proteins is dependent upon the product of the secB gene. Previous studies indicated that SecB promotes the export of the periplasmic maltose-binding protein (MBP) by preventing premature folding of the precursor MBP in the cytoplasm into an export-incompetent form. In this study, SecB has been purified to homogeneity and shown to be a soluble, cytoplasmic, multimeric protein composed of identical 17-kDa subunits. SecB was required for efficient in vitro translocation of MBP into inverted membrane vesicles. The addition of purified SecB to an in vitro system prepared from SecB-cells significantly enhanced MBP translocation. The purified protein also quantitatively retarded folding of precursor MBP into a stable, protease-resistant conformation in the absence of membranes. Finally, the inclusion of excess purified SecB in a SecB+ in vitro system significantly prolonged the time in which precursor MBP remained competent for posttranslational import into membrane vesicles.A number of components of the protein export machinery of Escherichia coli have been identified by genetic approaches [reviewed by Oliver (1)] and by biochemical approaches using in vitro protein translocating systems (2-4). The export of a subset of envelope proteins, including the periplasmic maltose-binding protein (MBP), is adversely affected by mutations in secB, a nonessential gene that maps near min 81 on the E. coli chromosome (5, 6). We have presented (7) evidence that the SecB protein functions as an antifolding factor that specifically interacts with the mature region of the precursor MBP (pre-MBP) to prevent its premature folding in the cytoplasm into a translocation-incompetent form. Kumamoto and Gannon (8) reached a similar conclusion by using a different experimental approach. Thus a specific biochemical function was assigned to the product of an E. coli sec gene, which complemented earlier work by Randall and Hardy (9) correlating the folding of pre-MBP into its stable tertiary structure in the cytoplasm with the loss ofexport competence. The essential role of protein conformation during membrane translocation has been recognized in eukaryotic cells as well (10). For example, unfolding factors that facilitate translocation of proteins into the endoplasmic reticulum and mitochondria have been described (11,12).An understanding ofprotein export in E. coli will be greatly aided by the purification and characterization of the individual components that mediate this process and eventual reconstitution of a complete protein translocating system in vitro. This study was undertaken to demonstrate the SecB dependence of MBP translocation in vitro and to purify biologically active SecB capable of interacting with newly synthesized pre-MBP to retard its folding and promote its import into membrane vesicles. MATERIALS AND METHODSIn Vitro MBP Synthesis and Translocation. MBP was synthesized in vitro by using a coupled E. coli transcriptiontranslation system, in the presence o...

The thymidine analog 3'-azido-3'-deoxythymidine (BW A509U; azidothymidine [AZT]) had potent bactericidal activity against many members of the family Enterobacteriaceae, including strains of Escherichia coli, Salmonella typhimurium, Klebsiella pneumoniae, Shigella flexneri, and Enterobacter aerogenes. AZT also had bactericidal activity against Vibrio cholerae and the fish pathogen Vibrio anguillarum. AZT had no activity against Pseudomonas aeruginosa, gram-positive bacteria, anaerobic bacteria, Mycobacterium tuberculosis, nontuberculosis mycobacteria, or,most fungal pathogens. Several lines of evidence indicated that AZT must be activated to the nucleotide level to inhibit cellular metabolism: (i) AZT was a substrate for E. coli thymidine kinase; (ii) spontaneously arising AZT-resistant mutants of E. coli ML-30 and S. typhimurium were deficient in thymidine kinase; and (iii) intact E. coli ML-30 cells converted [3H]AZT to its mono-, di-, and triphosphate metabolites. Of the phosphorylated metabolites, AZT-5'-triphosphate was the most potent inhibitor of replicative DNA synthesis in toluene-permeabilized E. coli pol A mutant cells. AZT-treated E. coli cultures grown in minimal medium contained highly elongated cells consistent with the inhibition of DNA synthesis. AZT-triphosphate was a specific DNA chain terminator in the in vitro DNA polymerization reaction catalyzed by the Klenow fragment of E. coli DNA polymerase I. Thus, DNA chain termination may explain the lethal properties of this compound against susceptible microorganisms.Nucleoside antibiotics have been under investigation for many years (27). Some of the most clinically effective antiviral agents currently in use are purine or pyrimidine nucleoside analogs (24). For example, ribavirin, a synthetic nucleoside similar in structure to guanosine and inosine, has potent in vitro activity against a broad spectrum of viruses, including the epidemic respiratory viruses (3,25). Two effective inhibitors of bacteria are 9-,B-D-arabinofuranosyladenine and 2',3'-dideoxyadenosine. reported the lethality of the former to a purinerequiring strain of Escherichia coli B. In this organism, 9-4-D-arabinofuranosyladenine markedly inhibited DNA synthesis and had virtually no effect upon RNA synthesis. In addition, 2',3'-dideoxyadenosine was shown to be lethal to selected strains of E. coli by irreversibly inhibiting DNA synthesis in susceptible microorganisms (5, 28).As a result of screening synthetic compounds for potential antimicrobial activity, we have observed that compound BW A509U (3'-azido-3'-deoxythymidine, referred to as AZT in this paper; Fig. 1) has potent, bactericidal in vitro activity against various members of the family Enterobacteriaceae. This report describes the extent of the in vitro growthinhibiting activity of AZT and proposes a mechanism to explain its lethal properties. In addition, the antibacterial activity of AZT is discussed in light of the recent finding that this compound inhibits human T-cell lymphotropic virus type III/lymphadenopathy-assoc...

Lamotrigine produces significantly fewer untoward cognitive and behavioral effects compared to topiramate (TPM) at the dosages, titrations, and timeframes employed in this study. The dosages employed may not have been equivalent in efficacy. Future studies are needed to delineate the cognitive and behavioral effects of TPM at lower dosages.